Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Stock Information for Milestone Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals to Present at Upcoming Conferences
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Milestone Pharmaceuticals Announces Proposed Public Offering
Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST(TM) (etripamil) Nasal Spray
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.